Ying Huang, formerly CEO of Legend Biotech, stepped into the CEO role at K2 Therapeutics as part of a C-suite overhaul. K2’s focus includes building a multimodal oncology pipeline and pursuing new prospects via licensing activity. The leadership transition comes shortly after Huang’s departure from Legend, during which Carvykti expanded from pipeline stage to commercialization and broadened label over time. For the industry, the move is a personnel signal that investors will watch for pipeline and partnering speed—especially in a market where execution timing matters for valuation.